PHIO - Rasio cepet phiopharma.com

Phio Pharmaceuticals (PHIO) specializes in developing cutting-edge medical drugs through gene modification. This market valuation chart reflects the 8.34 metric. Management efficiency is evidenced by achievements in immuno-oncology and the protection of intellectual property. The business remains largely independent of market volatility, as its progress is primarily driven by medical test results and the clinical implementation of new products.

Investors are assessing the issuer's resilience through its ability to cover short-term obligations solely using cash and accounts receivable, completely ignoring illiquid inventories. By analyzing the current quick ratio, one can determine the readiness of Phio Pharmaceuticals (PHIO) to pay third-party CRO/CMO contractors, which is critical given its fabless RNA drug development model and high dependence on external synthetic capacities.